出品 | 子弹财经作者 | 孟祥娜编辑 | 胡芳洁美编 | 倩倩审核 | 颂文近年来,在医药领域的众多创新成果中,GLP-1(胰高血糖素样肽-1)受体激动剂异军突起,已然成为行业内当之无愧的热门赛道。这类最初治疗糖尿病的药物,随着研究的深入和临床应用的拓展,不仅能有效控制血糖,还能使患者体重出现较为明显的下降,GLP-1受体激动剂也被冠以减肥“明星药”。12月17日,手握一种长效GLP-1受体...
Source Link出品 | 子弹财经作者 | 孟祥娜编辑 | 胡芳洁美编 | 倩倩审核 | 颂文近年来,在医药领域的众多创新成果中,GLP-1(胰高血糖素样肽-1)受体激动剂异军突起,已然成为行业内当之无愧的热门赛道。这类最初治疗糖尿病的药物,随着研究的深入和临床应用的拓展,不仅能有效控制血糖,还能使患者体重出现较为明显的下降,GLP-1受体激动剂也被冠以减肥“明星药”。12月17日,手握一种长效GLP-1受体...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.